Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $1,119.00

by · The Cerbat Gem

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty-two brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $1,119.00.

REGN has been the topic of several analyst reports. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th.

Get Our Latest Stock Analysis on REGN

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of REGN stock opened at $1,012.19 on Friday. Regeneron Pharmaceuticals has a 52-week low of $769.19 and a 52-week high of $1,211.20. The stock has a market cap of $111.53 billion, a price-to-earnings ratio of 29.90, a P/E/G ratio of 3.55 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm has a fifty day moving average of $1,122.57 and a 200-day moving average of $1,038.45.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the prior year, the company posted $8.79 EPS. The business’s revenue was up 12.3% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. B & T Capital Management DBA Alpha Capital Management acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $1,298,000. UMB Bank n.a. raised its holdings in Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 10 shares during the period. Adirondack Trust Co. raised its holdings in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares during the period. Wedmont Private Capital raised its holdings in Regeneron Pharmaceuticals by 4.5% during the 3rd quarter. Wedmont Private Capital now owns 1,496 shares of the biopharmaceutical company’s stock worth $1,490,000 after buying an additional 65 shares during the period. Finally, CWM LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock worth $2,389,000 after acquiring an additional 25 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

(Get Free Report

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories